{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T23:14:59Z","timestamp":1786403699169,"version":"build-2736575974"},"reference-count":93,"publisher":"Informa UK Limited","issue":"5","funder":[{"name":"paper was not"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Drug Safety"],"published-print":{"date-parts":[[2019,5,4]]},"DOI":"10.1080\/14740338.2019.1602606","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:17:40Z","timestamp":1554373060000},"page":"403-414","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":19,"title":["Review of the long-term safety of lomitapide: a microsomal triglycerides transfer protein inhibitor for treating homozygous familial hypercholesterolemia"],"prefix":"10.1080","volume":"18","author":[{"given":"Etienne","family":"Khoury","sequence":"first","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diane","family":"Brisson","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Roy","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Canada"},{"name":"Lipid Clinic, Chicoutimi Hospital, Chicoutimi, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9rald","family":"Tremblay","sequence":"additional","affiliation":[{"name":"Lipid Clinic, Chicoutimi Hospital, Chicoutimi, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Gaudet","sequence":"additional","affiliation":[{"name":"Clinical Lipidology and Rare Lipid Disorders Unit, Community Genomic Medicine Center, Department of Medicine, Universit\u00e9 de Montr\u00e9al and ECOGENE-21 Clinical and Translational Research Center, Chicoutimi, Canada"},{"name":"Lipid Clinic, Chicoutimi Hospital, Chicoutimi, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2019,5,16]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61476-1"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200318925"},{"issue":"1","key":"CIT0003","first-page":"49","volume":"25","author":"Marais AD.","year":"2004","journal-title":"Clin Biochem Rev"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.855"},{"issue":"2","key":"CIT0005","first-page":"54","volume":"124","author":"Gaudet D","year":"1995","journal-title":"Union Med Can"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0000000000000488"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2018.09.005"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61374-X"},{"key":"CIT0009","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.117.310217"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1111\/j.1527-3466.2002.tb00097.x"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1007\/s11936-006-0049-z"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2009.06.010"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1111\/1755-5922.12105"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.03.008"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1705994"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.07.071"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.07.068"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/j.ahj.2015.01.008"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-016-0579-0"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-med-051215-030943"},{"key":"CIT0021","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2018.06.859"},{"key":"CIT0022","author":"Gossios T","year":"2018","journal-title":"Curr Pharm Des"},{"key":"CIT0023","unstructured":"Juxtapid (lomitapide) capsules, for oral use. Initial u.S. Approval. 2012. [cited 2018 Nov]. Available from: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/label\/2012\/203858s000lbl.Pdf"},{"key":"CIT0024","unstructured":"Clinical review(s) of lomitapide for treating patients with homozygous familial hypercholesterolemia. Fda drug approvals and databases. Washington, dc: Fda\/center for drug evaluation and research; 2012. [cited 2018 Nov]. Available from: http:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/nda\/2012\/203858orig1s000medr.Pdf"},{"key":"CIT0025","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S36641"},{"key":"CIT0026","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa061189"},{"key":"CIT0027","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)61731-0"},{"key":"CIT0028","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2013.13309"},{"key":"CIT0029","doi-asserted-by":"publisher","DOI":"10.1016\/j.medcli.2014.11.002"},{"key":"CIT0030","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.05.001"},{"key":"CIT0031","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.02.009"},{"key":"CIT0032","doi-asserted-by":"publisher","DOI":"10.5551\/jat.34777"},{"key":"CIT0033","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.113.001292"},{"key":"CIT0034","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2003.11.001"},{"issue":"6","key":"CIT0035","first-page":"1298","volume":"57","author":"Narcisi TM","year":"1995","journal-title":"Am J Hum Genet"},{"key":"CIT0036","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.04.010"},{"key":"CIT0037","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbalip.2016.01.014"},{"key":"CIT0038","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2015-2731"},{"key":"CIT0039","doi-asserted-by":"publisher","DOI":"10.1097\/MOL.0b013e32836139df"},{"key":"CIT0040","unstructured":"Product monograph, juxtapid, lomitapide capsules. [cited 2017 Aug]. Available from: http:\/\/www.Aegerion.Ca\/collateral\/documents\/canada-english\/final%20pristine%20monograph%20copy.Pdf"},{"key":"CIT0041","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028208"},{"key":"CIT0042","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60284-X"},{"key":"CIT0043","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehr148"},{"key":"CIT0044","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.07.081"},{"key":"CIT0045","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.03.091"},{"key":"CIT0046","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2015.11.011"},{"key":"CIT0047","doi-asserted-by":"crossref","first-page":"A12450","DOI":"10.1161\/circ.132.suppl_3.12450","volume":"132","author":"Blom D","year":"2015","journal-title":"Circulation"},{"key":"CIT0048","doi-asserted-by":"publisher","DOI":"10.5551\/jat.44107"},{"key":"CIT0049","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2015.03.014"},{"key":"CIT0050","doi-asserted-by":"publisher","DOI":"10.1080\/13543784.2016.1254187"},{"key":"CIT0051","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M300094-JLR200"},{"key":"CIT0052","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2480"},{"key":"CIT0053","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-017-0214-7"},{"key":"CIT0054","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0531-x"},{"key":"CIT0055","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.08.005"},{"key":"CIT0056","doi-asserted-by":"publisher","DOI":"10.5551\/jat.45708"},{"key":"CIT0057","doi-asserted-by":"publisher","DOI":"10.5551\/jat.ED069"},{"key":"CIT0058","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0841-3"},{"key":"CIT0059","doi-asserted-by":"publisher","DOI":"10.2459\/JCM.0000000000000620"},{"issue":"3","key":"CIT0060","first-page":"A10818","volume":"132","author":"Blom D","year":"2015","journal-title":"Circulation"},{"key":"CIT0061","unstructured":"Fda briefing document, nda 203568. Mipomersen sodium injection 200 mg\/ml. Materials for the endocrinologic and metabolic drugs advisory committee meeting, 18 october 2012. [cited 2018 Nov]. Available from: https:\/\/www.Accessdata.Fda.Gov\/drugsatfda_docs\/nda\/2013\/203568orig1s000pharmr.Pdf."},{"key":"CIT0062","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2016.05.028"},{"key":"CIT0063","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/eht549"},{"key":"CIT0064","doi-asserted-by":"publisher","DOI":"10.1586\/17512433.2016.1162095"},{"key":"CIT0065","doi-asserted-by":"publisher","DOI":"10.1007\/s40256-014-0077-0"},{"key":"CIT0066","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.112.104125"},{"key":"CIT0067","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0049006"},{"key":"CIT0068","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2014.08.002"},{"key":"CIT0069","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2005.06.018"},{"key":"CIT0070","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2007.05.003"},{"key":"CIT0071","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.01.004"},{"issue":"1","key":"CIT0072","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3909\/ricm0834","volume":"18","author":"Won JI","year":"2017","journal-title":"Rev Cardiovasc Med"},{"key":"CIT0073","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.10.007"},{"key":"CIT0074","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2017.1340941"},{"key":"CIT0075","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2016.12.019"},{"key":"CIT0076","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.04.114"},{"key":"CIT0077","unstructured":"Juxtapid (lomitapide) capsules, risk evaluation and mitigation strategy (rems). [cited 2017 Aug]. Available from: https:\/\/www.Fda.Gov\/downloads\/drugs\/drugsafety postmarketdrugsafetyinformationforpatients andproviders\/ucm333438.Pdf"},{"key":"CIT0078","unstructured":"Summary of the european public assessment report (epar) for lojuxta. European medicines agency, science medicines health. Canary wharf, london, uk: European medicines agency; 2016. [cited 2016 Dec]. Available from: http:\/\/www.Ema.Europa.Eu\/docs\/en_gb\/document_library\/epar_-_summary_for_the_public\/human\/002578\/wc500148552.Pdf"},{"key":"CIT0079","unstructured":"Assessment report of the committee for medicinal products for human use (chmp) for lojuxta. European medicines agency, science medicines health. Canary wharf, london, uk: European medicines agency; 2013. [cited 2019 Jan]. Available from: https:\/\/www.Ema.Europa.Eu\/documents\/assessment-report\/lojuxta-epar-public-assessment-report_en.Pdf"},{"key":"CIT0080","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosissup.2014.07.005"},{"key":"CIT0081","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.92.9.2419"},{"key":"CIT0082","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199511163332001"},{"key":"CIT0083","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1701329"},{"key":"CIT0084","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2016.08.002"},{"key":"CIT0085","doi-asserted-by":"publisher","DOI":"10.1007\/s11886-018-1004-9"},{"key":"CIT0086","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.12.067"},{"key":"CIT0087","unstructured":"Pharmacoeconomic evaluation. Cdr submission: juxtapid\u2122 (lomitapide), 5 mg, 10 mg and 20 mg capsules. Company: aegerion pharmaceuticals (canada) ltd. [confidential manufacturer\u2018s submission]. Toronto: Aegerion pharmaceuticals (canada) ltd. [2014 Jul 7."},{"key":"CIT0088","unstructured":"Kei series on patents that fail to disclose u.S. Government funding. The undisclosed rader patents for juxtapid, 19 march 2018. [last accessed Feb 2019]. Available from: https:\/\/www.Keionline.Org\/wp-content\/uploads\/2018\/03\/juxtapid-failure2disclose-daniel-rader-19mar2018.Pdf"},{"key":"CIT0089","doi-asserted-by":"publisher","DOI":"10.1038\/ncpcardio1250"},{"key":"CIT0090","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.105.606442"},{"key":"CIT0091","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.11.069"},{"key":"CIT0092","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2010.01.003"},{"key":"CIT0093","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M002915"}],"container-title":["Expert Opinion on Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14740338.2019.1602606","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T06:59:04Z","timestamp":1663225144000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14740338.2019.1602606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5,4]]},"references-count":93,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5,4]]}},"alternative-id":["10.1080\/14740338.2019.1602606"],"URL":"https:\/\/doi.org\/10.1080\/14740338.2019.1602606","relation":{},"ISSN":["1474-0338","1744-764X"],"issn-type":[{"value":"1474-0338","type":"print"},{"value":"1744-764X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,5,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ieds20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2018-12-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-03-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}